Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 212,357 shares, an increase of 71.6% from the August 15th total of 123,737 shares. Based on an average trading volume of 1,455,508 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Several research firms have weighed in on INDP. Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Indaptus Therapeutics has a consensus rating of “Sell”.

Indaptus Therapeutics Stock Down 11.8%

Shares of NASDAQ:INDP traded down $0.43 during midday trading on Wednesday, reaching $3.21. The company’s stock had a trading volume of 1,187,470 shares, compared to its average volume of 624,465. The stock has a fifty day moving average of $1.77 and a 200 day moving average of $2.15. Indaptus Therapeutics has a twelve month low of $0.92 and a twelve month high of $8.57. The firm has a market capitalization of $427.70 million, a PE ratio of -0.51 and a beta of 1.17.

Indaptus Therapeutics (NASDAQ:INDP) last posted its earnings results on Thursday, August 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.57) by $1.55.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.

Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies.